Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director · 10% owner | April 06, 2023 | April 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date April 06, 2023 · Filed April 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-04-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-04-06 · Exercise / conversion · Acquired 60,000 · Balance 60,000 Row 2 · 2023-04-06 · Sale · Disposed 60,000 · Balance 0 F1: The sale reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022. F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $17.03 to $17.70. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.41 · Expires 2027-08-23 | Direct | 294,000 |
Reported balance
After 2023-04-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-06 · Exercise / conversion · Disposed 60,000 · Balance 294,000 F4: The options are fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 8,546,750 |
Reported balance
Holding disclosure · report date 2023-04-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,546,750 F3: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Holdings"). By virtue of the Reporting Person's relationship with BioXcel LLC and Holdings, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022.
F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $17.03 to $17.70. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Holdings"). By virtue of the Reporting Person's relationship with BioXcel LLC and Holdings, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
F4: The options are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2023 Filed Apr 10, 2023 22:20 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionStock Options · Derivative | 60,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001104659-23-043694 · tm2312272-1_4seq1.xml · derivative · entry 4 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 294,000 Underlying: Common Stock · 60,000 shares Expires 2027-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 22:20 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 60,000 | $17.32 | $1,039,200.00 |
DisclosureSEC source: 0001104659-23-043694 · tm2312272-1_4seq1.xml · nonDerivative · entry 2 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $17.03 to $17.70. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 22:20 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 60,000 | $0.41 | $24,600.00 |
DisclosureSEC source: 0001104659-23-043694 · tm2312272-1_4seq1.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionStock Options · Derivative | 25,889 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · derivative · entry 9 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,000 Underlying: Common Stock · 25,889 shares Expires 2027-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 800 | $22.93 | $18,344.00 |
DisclosureSEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 6 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1. F5 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $22.90 to $23.04. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 25,089 | $22.32 | $559,986.48 |
DisclosureSEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 5 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1. F4 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $21.90 to $22.89. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 25,889 | $0.41 | $10,614.49 |
DisclosureSEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 4 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2023 Filed Jan 7, 2023 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionStock Options · Derivative | 34,111 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · derivative · entry 8 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,889 Underlying: Common Stock · 34,111 shares Expires 2027-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| January 04, 2023 Filed Jan 7, 2023 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 9,821 | $22.21 | $218,124.41 |
DisclosureSEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 3 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $22.0367 to $22.42. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2023 Filed Jan 7, 2023 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 24,290 | $21.59 | $524,421.10 |
DisclosureSEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 2 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,821 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $21.03 to $22.0263. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2023 Filed Jan 7, 2023 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 34,111 | $0.41 | $13,985.51 |
DisclosureSEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2022 Filed Feb 14, 2023 21:44 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 291,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-021791 · tm236671-2_5seq1.xml · nonDerivative · entry 3 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,546,750 F3 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's spouse receieved by gift shares of Parent representing a 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F3 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's spouse receieved by gift shares of Parent representing a 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| November 15, 2022 Filed Feb 14, 2023 21:44 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 291,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-021791 · tm236671-2_5seq1.xml · nonDerivative · entry 2 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,546,750 F2 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| November 15, 2022 Filed Feb 14, 2023 21:44 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 145,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-021791 · tm236671-2_5seq1.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,546,750 F1 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.7% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F1 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.7% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionStock Options · Derivative | 32,550 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · derivative · entry 7 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,000 Underlying: Common Stock · 32,550 shares Expires 2027-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options are fully vested and exercisable Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 32,550 | $15.00 | $488,250.00 |
DisclosureSEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · nonDerivative · entry 4 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $15.00 to $15.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 32,550 | $0.41 | $13,345.50 |
DisclosureSEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · nonDerivative · entry 3 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionStock Options · Derivative | 27,450 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · derivative · entry 6 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,550 Underlying: Common Stock · 27,450 shares Expires 2027-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options are fully vested and exercisable Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 27,450 | $15.00 | $411,750.00 |
DisclosureSEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · nonDerivative · entry 2 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 27,450 | $0.41 | $11,254.50 |
DisclosureSEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:23 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 473,250 | $30.83 | $14,589,492.98 |
DisclosureSEC source: 0001104659-21-086946 · tm2119762-8_4seq1.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 8,546,750 F1 · kind: On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions. F1 · price: On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions. F2 · balance_after: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F1 · ownership.nature: On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions. F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F3 · ownership.nature: Does not include 1,000 shares of the Issuer's common stock inadvertently previously reported as indirectly beneficially owned by The Sunanda Family Trust. Such shares are no longer held by the Reporting Person following the gift disposition of such shares on December 1, 2020. Read SEC document |
| April 06, 2021 Filed Feb 14, 2022 22:37 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 102,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023281 · tm226624-1_5seq1.xml · nonDerivative · entry 4 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,546,750 F4 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person's spouse gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F4 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person's spouse gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| April 06, 2021 Filed Feb 14, 2022 22:37 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 130,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023281 · tm226624-1_5seq1.xml · nonDerivative · entry 3 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,546,750 F3 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse receieved by gift shares of Parent representing a 1.6% economic interest in Parent from the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F3 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse receieved by gift shares of Parent representing a 1.6% economic interest in Parent from the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| April 06, 2021 Filed Feb 14, 2022 22:37 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 130,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023281 · tm226624-1_5seq1.xml · nonDerivative · entry 2 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,546,750 F2 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 1.6% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 1.6% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| April 06, 2021 Filed Feb 14, 2022 22:37 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 102,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023281 · tm226624-1_5seq1.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,546,750 F1 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F1 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| December 01, 2020 Filed Feb 16, 2021 22:28 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 185,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024416 · tm216714-2_5seq1.xml · nonDerivative · entry 3 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,020,000 F2 · balance_after: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse gifted shares of Parent representing a 2.05% economic interest in Parent to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse gifted shares of Parent representing a 2.05% economic interest in Parent to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| December 01, 2020 Filed Feb 16, 2021 22:28 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 185,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024416 · tm216714-2_5seq1.xml · nonDerivative · entry 2 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,020,000 F1 · balance_after: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing a 2.05% economic interest in Parent to his spouse. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F1 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing a 2.05% economic interest in Parent to his spouse. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| July 24, 2020 Filed Feb 16, 2021 22:28 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024416 · tm216714-2_5seq1.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 24, 2020 Filed Feb 16, 2021 22:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | OtherCommon Stock | 80,000 | $60.76 | $4,860,800.00 |
DisclosureSEC source: 0001104659-21-024409 · tm216714-1_4seq1.xml · nonDerivative · entry 4 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 F4 · kind: See footnote (2). These securities were acquired as the result of the distribution of the Issuer's common stock by Parent to the Reporting Person in return for the cancellation of a proportional number of shares owned in Parent owned by the Reporting Person. Read SEC document |
| July 24, 2020 Filed Feb 16, 2021 22:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | OtherCommon Stock | 160,000 | $60.76 | $9,721,600.00 |
DisclosureSEC source: 0001104659-21-024409 · tm216714-1_4seq1.xml · nonDerivative · entry 3 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 9,020,000 F2 · kind: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder. F3 · kind: By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F2 · balance_after: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder. F3 · balance_after: By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder. F3 · ownership.nature: By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| February 24, 2020 Filed May 13, 2020 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Disposition to issuerCommon Stock | 300,000 | $30.08 | $9,024,000.00 |
DisclosureSEC source: 0001104659-20-061009 · a4.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,180,000 F1 · date: The transaction was effected by BioXcel Corporation. Effective April 23, 2020, BioXcel Corporation merged with and into BioXcel LLC. F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and shareholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| January 02, 2020 Filed Apr 28, 2020 20:47 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001104659-20-052445 · a4.xml · derivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 2, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through the relevant vesting dates. Read SEC document |
| April 01, 2019 Filed Feb 16, 2021 22:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024409 · tm216714-1_4seq1.xml · nonDerivative · entry 2 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 1,000 F1 · ownership.nature: Shares held by The Sunanda Family Trust. Read SEC document |
| April 01, 2019 Filed Feb 16, 2021 22:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024409 · tm216714-1_4seq1.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 21:17 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 1,000 | $4.92 | $4,915.00 |
DisclosureSEC source: 0001104659-18-070832 · a4.xml · nonDerivative · entry 1 Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · ownership.direct: By Krishnan Nandabalan and Suganthi Balasubramanian JTWROS Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.